Organization | Bioikos Ambiente Srl

Bioikos Ambiente Srl Report issue

For profit Phase 2 Phase 3

Founded: Bologne Italy (1993)

Organization Overview

First Clinical Trial

2017

NCT03542461

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Bioikos Ambiente Srl | Yghea, CRO Division of Bioikos Ambiente srl | YGHEA, CRO Division of Ecol Studio spa

Active Ingredients

Drugs in Phase 3 Trials (5)

acetaminophen (tylenol) (1 trial)

ketoprofen (orudis) (1 trial)

methoxyflurane (penthrane) (1 trial)

morphine (1 trial)

nivolumab (opdivo) (1 trial)

Drugs in Phase 2 Trials (6)

atezolizumab (Tecentriq) (2 trials)

bevacizumab (avastin) (1 trial)

cabozantinib (cometriq) (1 trial)

carboplatin (paraplatin) (1 trial)

etoposide (vepesid) (1 trial)

reboxetine (Edronax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Apnea (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 11